ANTI-TUBERCULOUS THERAPY AND ACUTE LIVER-FAILURE

被引：69

作者：

MITCHELL, I ^{[1
]}

WENDON, J ^{[1
]}

FITT, S ^{[1
]}

WILLIAMS, R ^{[1
]}

机构：

[1] UNIV LONDON KINGS COLL HOSP,INST LIVER STUDIES,LONDON SE5 9RS,ENGLAND

来源：

LANCET | 1995年 / 345卷 / 8949期

关键词：

D O I：

10.1016/S0140-6736(95)90468-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The incidence of tuberculosis has been increasing since 1987, exposing a greater number of patients to the risks of three potentially hepatotoxic drugs, isoniazid, rifampicin, and pyrazinamide. Awareness of potentially severe drug hepatotoxic reactions is vital because fulminant hepatic failure is a devastating and often fatal condition without liver transplantation. We report four cases of fulminant hepatic failure caused by rifampicin, isoniazid, or both. These cases highlight the need for stricter adherence to and review of current guidelines on liver function tests after starting anti-tuberculous therapies.

引用

页码：555 / 556

页数：2

共 10 条

[1]

BRYRD RB, 1979, JAMA-J AM MED ASSOC, V241, P1239

[2] THE EMERGENCE OF DRUG-RESISTANT TUBERCULOSIS IN NEW-YORK-CITY [J].

FRIEDEN, TR ;

STERLING, T ;

PABLOSMENDEZ, A ;

KILBURN, JO ;

CAUTHEN, GM ;

DOOLEY, SW .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (08) :521-526

[3] ISONIAZID-ASSOCIATED HEPATITIS - REPORT OF AN OUTBREAK [J].

GARIBALDI, RA ;

FEREBEE, SH ;

GREGG, MB ;

DRUSIN, RE .

AMERICAN REVIEW OF RESPIRATORY DISEASE, 1972, 106 (03) :357-+

[4]

GROSSET J, 1983, REV INFECT DIS, V5, pS440

[5]

HUGHES R D, 1991, Gut, pS86

[6]

MADDREY WC, 1973, ANN INTERN MED, V79, P791

[7] EARLY INDICATORS OF PROGNOSIS IN FULMINANT HEPATIC-FAILURE [J].

OGRADY, JG ;

ALEXANDER, GJM ;

HAYLLAR, KM ;

WILLIAMS, R .

GASTROENTEROLOGY, 1989, 97 (02) :439-445

[8]

1994, LANCET, V344, P277

[9]

1990, THORAX, V45, P403

[10]

1994, AM J REPSIR CRIT CAR, V149, P1359

← 1 →